All In Biotech

Drug Trial Radar · NCT03213002

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

Phase I/II Study of Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed Glioblastoma (GBM)

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

67

Planned (sponsor's estimate)

Start

Mar 25, 2018

Primary completion

Jun 2028

Study completion Jun 2029

Sponsor

Lead sponsor
Northwell HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 11, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly diagnosed glioblastoma multiforme (GBM). Capecitabine is an oral chemotherapy that is given to patients with other types of cancer. The study will evaluate whether the dosage of 1500 mg/m2 of capecitabine is tolerable after radiation, when taken along with temozolomide. It will also try to determine if the medication capecitabine helps patients respond to treatment for a longer period of time compared to just temozolomide alone, which is the standard of care.

Conditions

  • Glioblastoma Multiforme (GBM)
  • Glioblastoma
  • Glioma of Brain
  • Glioblastoma, Adult
  • Brain Tumor
  • Brain Tumor, Primary
  • Brain Tumor Adult
  • Cancer
  • Brain Cancer

Interventions

  • CapecitabineDrug

    Capecitabine at 1500 mg/m2

  • TemozolomideDrug

    Temozolomide at 150 mg/m2 - 200 mg/m2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: 6 months
  2. Overall Survival (OS)Time frame: 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lenox Hill Brain Tumor Center

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.